|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
| Molecular Diagnostics 2007: Technologies, Companies, Products, Applications and Worldwide Outlook |
|
|
|
|
€ 1 196,00 |
Editeur
: |
Fuji Keizai USA |
Langue
: |
Anglais |
Date de publication : |
Mai 2007 |
Taille du document : |
163 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Functional Proteomics and Emerging Bio-IT market pages | Novembre 2002 |
The proteomic technique is not only limited to the study of one or few cellular products but also allows for qualitative and a quantitative measurement of several hundreds of proteins produced during |
250,00 €
|
| |
| |
03-052B: The DNA Purification Market: Keys to Success for Commercial Kit Suppliers 152 pages | Octobre 2003 |
This report is designed to help life science product managers understand customers in the DNA purification market and the factors that drive their purchasing behavior |
1 280,00 €
|
| |
| |
03-052A: Protein Purification Systems: Market Opportunities for Research Product Suppliers 163 pages | Octobre 2003 |
This report will help suppliers exploit opportunities to differentiate themselves from their competitors and develop more advanced protein purification tools |
960,00 €
|
| |
| |
Genomic Revolution: Trends & Opportunities 30 pages | Octobre 2002 |
Computational advancements in Genomic technology have brought a revolution in the field of application of Pharmaco-Therapy. Companies are diversifying their business prospect from medical chemistry |
600,00 €
|
| |
| |
Carbohydrate Therapeutics 180 pages | Décembre 2000 |
Carbohydrates are the only class of biological molecule (there are four main classes: nucleic acids, proteins, lipids, and carbohydrates - commonly known as sugars), that can be found in direct associ |
1 400,00 €
|
| |
| |
Antisense Therapeutics IRCD pages | Juin 2001 |
Antisense molecules are stretches of single-stranded nucleic acid that target and bind with a specific mRNA, interfering with and even preventing the translation or over-expression of the protein |
1 026,17 €
|
| |
| |
03-026: The Market for Tissue Microarrays 134 pages | Juillet 2003 |
This report provides vital information on end-users’ scientific objectives, instrumentation for production and analysis of TMAs, outsourcing practices and preferred TMA suppliers |
640,00 €
|
| |
| |
Integrating Genomics: The Next Generation 124 pages | Février 1999 |
Genomics research : Understand the key technologies including target identification (genome mapping, random sequencing and two-hybrid assay), target validation/assay development and current appli |
795,00 €
|
| |
| |
Pharmacogenomics 160 pages | Décembre 2000 |
The Human Genome Project and numerous corporate and academic human gene sequencing efforts have revealed, among others, that genes exist in the population in numerous mutated forms, some of which |
1 400,00 €
|
| |
| |
03-019: The Market for Microbial Genotyping Products: Research and Testing Applications 183 pages | Juin 2003 |
The report identifies the kits, reagents and instrumentation that are most commonly used for microbial identification and analysis in both the research and testing arenas |
800,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Molecular Diagnostics 2007: Technologies, Companies, Products, Applications and Worldwide Outlook |
|
|
This report reviews, analyzes and sizes the combined molecular diagnostics product and clinical lab services markets. The study uncovers interesting information about key equipment, IVD consumables, reagents, software and services that are marketed to clinical diagnostic labs located at independent companies, hospitals, HMOs, doctors cooperatives and healthcare centers of all kinds in the developed and developing worldwide regions. This report assesses the market and maps the competitors in this market landscape with more than 85 companies identified. The financial section sizes the market and discusses the five-year revenue projection to 2011. This study segments the market by major product and service areas, by technology, by disease/ application, and by test sample material. The report also segments the market by major world regions to see the growth opportunity. This study reviews and analyzes major company alliances, M&As during the last two years. Large data tables summarize the alliances and M&As. The alliance table presents a large amount of partnering information. This report reviews the molecular diagnostic technology and business trends over the next three to five years. Large and small analytical tables help the reader quicky understand the trend information. The study methodolgy uses primary information that was gathered from numerous sources including in-person interviews and discussions, telephone interviews, and surveys, attendance at business presentations at healthcare technical and financial conferences as well a through secondary research. This research report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and the like. More than 51 detailed tables or figures provide key data about items such as strategic alliances, M&As, market size, segments and the like. This report includes 30 company profiles that provide the reader a snapshot of the companies’ focus or activities. The provided Internet links help readers access companies’ own web sites for further review.
|
|
1. Overview of Molecular Diagnostic Tests 1.1 Gene-Based and ‘Omics’-Based Biomarkers Enable Molecular Diagnostics 1.1.1 Molecular Diagnostics (J added) 1.2 Diagnostic Industry Competitive Overview 1.2.1 WW Molecular Diagnostics IVD Business 1.2.2 WW Molecular Diagnostics Lab Services 1.2.3 Leading Molecular Diagnostics IVD Makers 1.2.4 Leading Molecular Diagnostics IVD Lab Services 1.3 Advances in Molecular Diagnostics 1.3.1 FDA View of Biomarkers for Molecular Diagnostic Field 1.3.2 Genetic Tests for Multiple Gene Based Diseases 1.3.3 Multiplexed Protein Patterns Become Molecular Diagnostics 1.3.4 DNA Methylation Tests 1.4 Developing Molecular Diagnostics 1.4.2 Esoteric ‘Home Brew’ Molecular Diagnostics Marketed as Services 1.4.3 Developing a Test into an In Vitro Diagnostic 1.4.4 Product Prices and the $3,200 Test! 1.4.5 Healthcare Reimbursement Issues
2. Company Activities and Strategies 2.1 Major Market Participants by Disease Segments 2.2 Important Findings or Special Notes 2.2.1 Findings of Companies in Molecular Diagnostics by Sample Material 2.2.2 Findings of Companies in Molecular Diagnostics by Major Disease 2.2.3 Findings of Companies in Molecular Diagnostics by Product ‘Status’
3. Technologies Used in Developing Molecular Diagnostics 3.1 Technologies: Current Status & Next Stage Development Status 3.2 Overview of Technologies Used in Molecular Diagnostics 3.3 Technologies and Molecular Diagnostics Products: Current and Next Stage Development 3.4 Commercial Implications of Clinical Molecular Diagnostics
4. Alliances and R&D Activity in Molecular Diagnostics 4.1 Overview of Strategic Alliances & R&D in Molecular Diagnostics 4.1.1 Alliance Types 4.1.2 Molecular Diagnostic Alliances for R&D at a Glance 4.1.3 Alliances in Molecular Diagnostics Gained Momentum in 2006 4.2 Summary of Molecular Diagnostics in Medical Research 4.3 R&D Activity by Diseases or Applications 4.3.1 Summary of R&D Activity 4.3.2 Details of R&D Activity
5. Market Size and Forecast for Molecular Diagnostics 5.1 Market Overview: Molecular Diagnostic (MDx) Products & Clinical Lab Servic 5.2 WW Molecular Diagnostic (MDx) Product/ Market Trends 5.2.1 Examples of Selected MDx Equipment and Consumable Products 5.2.2 Examples of Selected MDx Lab Services 5.3 Molecular Diagnostic (MDx) Total WW Market Size 5.3.1 Total WW MDx Market Size, 2006-2011 5.3.2 Market Size by Major Segments 5.4 Leading Molecular Diagnostic Manufacturers’ Shares 5.5 WW Molecular Diagnostic Product Market Size by Disease Segments 5.6 WW Molecular Diagnostic Product Market Size by Test Material Segments 5.7 WW Molecular Diagnostic Product Market Size by Technologies 5.8 WW Molecular Diagnostic Product Market Size by Region 5.9 WW Molecular Diagnostic Lab Services Market Size by Disease and Regions 5.9.1 MDx Lab Services Market Size by Disease 5.9.2 WW Molecular Diagnostic Lab Services Market Size by Regions
6. Future Directions 6.1 Key Trends for Molecular Diagnostics 6.1.1 Infectious Disease Testing 6.1.2 Interest in Cancer Tests Growing 6.1.3 Future Direction for CNS Disease Tests 6.1.4 Future Direction of Genetic Testing and PGx Tests 6.2 Top Opportunities for the Future 6.2.1 Government Regulators Driving Future Opportunities 6.2.2 Emerging Personalized Medicine and Timeline 6.3 Main Challenges 6.3.1 High Costs of Molecular Diagnostics 6.3.2 Acute Shortages of Diagnostics in the Developing World 6.3.3 Worldwide Regulatory Delays in Approving New Tests 6.3.4 Insurance Reimbursement Issues
7. Activities of Molecular Diagnostics Companies 7.1 Large Diagnostic Lab Services 7.1.1 BML, Inc. 7.1.2 Diagnosticos Da America S.A. (DASA) 7.1.3 LabCorp 7.1.4 Quest Diagnostics, Inc. 7.1.5 Unilabs Group 7.2 Small Diagnostic Lab Services 7.2.1 diaDexus, Inc. 7.2.2 Myriad Genetics, Inc. 7.2.3 Veridex, LLC (J&J Co.) 7.2.4 Genomic Health, Inc. 7.2.5 Agendia B.V. 7.3 Large MDx Company 7.3.1 Abbott Molecular 7.3.2 BD Diagnostics 7.3.3 Digene Corporation 7.3.4 Beckman Coulter, Inc. 7.3.5 bioMérieux SA 7.3.6 Gen-Probe, Inc. 7.3.7 Roche Molecular Diagnostics 7.3.8 Siemens Medical Solutions Diagnostics 7.4 Point of Care MDx 7.4.1 BioSite, Inc. 7.4.2 Cepheid 7.5 Pure Play MDx 7.5.1 Celera Group 7.5.2 Chiron Corporation (Novartis) 7.5.3 Dako A/S 7.5.4 Exact Sciences Corporation 7.5.5 Innogenetics NV 7.6 DNA Methylation MDx 7.6.1 Orion Genomics LLC 7.6.2 Epigenomics AG 7.7 Array Platforms 7.7.1 Affymetrix, Inc. 7.7.2 Luminex Corporation 7.7.3 Nanogen, Inc.
8. Appendix 8.1 Major Disease Population Sizes 8.2 Companies Mentioned in This Report
LIST OF TABLES
Table 1. Molecular IVD Test Applications Table 2. Top Molecular Diagnostics IVD Players Table 3. Top Independent MDx IVD Lab Services Players Table 4. Typical Molecular Diagnostic IVD Development Path Table 5. Market Participants by Disease, Company, MDx Products (n=356) Table 6. Company Activities by Sample Material Totals and Shares Table 7. Company Activities by Major Disease Totals and Shares Table 8. Company Activities by ‘Product Status’ Segment Totals and Shares Table 9. Technologies: Current Status & Next Stage Development by Count Table 10. Technologies Market Share: 2006 vs. 2009 vs. 2011 by Product Pipelines Table 11. Technologies, Major Companies and Relationship Table 12. Technologies and MDx Products: Current and Next Stage Development Table 13. Vendor Competition by Nucleic Acid Amplification Technologies for Clinical Molecular Diagnostics and by Estimated Shares and Revenues Table 14. Strategic Alliances Summary by Alliance Type, 2004 to 2007 Table 15. Summary of M&As by Year, Buyer, Alliance Type, Size, 2004 to 2007 Table 16. Alliances Summary by Major Diseases, Jan-2004 to Mar-2007 Table 17. Alliances for Molecular Diagnostics by Major Disease, 2007 Table 18. Alliances for Molecular Diagnostics by Major Disease, 2006 Table 19. Alliances for Molecular Diagnostics by Major Disease, 2005 Table 20. Alliances for Molecular Diagnostics by Major Disease, 2004 Table 21. Examples of Selected MDx Equipment and Consumable Products Table 22. Examples of Selected MDx Lab Services and Prices Table 23. Total WW MDx Market Size, 2006-2011 Table 24. WW MDx Market Size and Forecast by Major Segments Table 25. Molecular Diagnostic Manufacturer Revenues ($M) & Shares (%) Table 26. MDx Products by Major Diseases/ Applications & Revenues Table 27. MDx Products by Test Material & Revenues Table 28. MDx Products by Technology & Revenues Table 29. MDx Product Market Size by WW Regions Table 30. Molecular Diagnostic Lab Services by Disease Segments Table 31. MDx Clinical Lab Services by WW Regions and Revenues Table 32. Future Direction of Infectious Disease Tests Table 33. Future Direction of Cancer Companion Tests and Targeted Medicine Table 34. Future Direction of Cancer Tests Table 35. CNS Tests Likely in Five Years Table 36. Future Direction of Pharmacogenomics (PGx) Tests Table 37. Future Genetic Tests for Risk Prediction Table 38. Selected Companion Diagnostics (PGx) and Targeted Therapies Table 39. Estimated Patient Populations by Disease in the Developed World Table 40. Top Health Risk Factors Leading to Death in the Developed World Table 41. Companies Mentioned in This Report
LIST OF ILLUSTRATIONS
Figure 1. WW Molecular Diagnostics Business Figure 2. The Fastest Growing IVD and Lab Services Businesses Figure 3. Total WW MDx Market Size, 2006-2011 Figure 4. WW MDx Market Size by Major Segments Figure 5. MDx Products by Major Diseases/ Applications & Revenues Figure 6. MDx Products by Test Material & Revenues Figure 7. MDx Products by Technology & Revenues Figure 8. MDx Product Market Size by WW Regions Figure 9. Molecular Diagnostic Lab Services by Disease Segments Figure 10. MDx Clinical Lab Services by WW Regions and Revenues
|
|
|
PPLSEN
|
|
|
|
|